The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
There is great variation in the carbon isotope composition of amino acids within a single organism. In cyanobacteria, Macko et al. observed a ~30‰ range in δ13C values amongst the amino acids. Amino acids produced from the same precursors also had widely varying compositions. It is difficult to explain these trends because of limited data on the kinetic isotope effects associated with reactions that synthesize amino acid carbon skeletons. Nevertheless, some insights can be gained by applying the logic above to the reaction networks responsible for amino acid biosynthesis. Consider the amino acids synthesized from pyruvate. Pyruvate is produced during glycolysis and can be decarboxylated by pyruvate dehydrogenase to generate acetyl groups. These acetyl groups enter the citric acid cycle as acetyl-CoA or can be used to synthesize lipids. There is a large kinetic isotope effect associated with this reaction, so the remaining pyruvate pool becomes enriched in 13C relative to the acetyl groups. This enriched pyruvate can be transaminated to produce alanine. In the experiments by Macko et al., alanine indeed had a δ13C value slightly higher than that of cyanobacterial photosynthate. Valine is synthesized by the addition of a 13C depleted acetyl group to pyruvate. Consistent with this mechanism, Takano et al. found valine to be depleted in 13C relative to alanine in anaerobic methanotrophic archaea. However, in cyanobacteria, Macko et al. observed a higher δ13C value for valine than alanine.
== History == Ketamine was first synthesized in 1962 by Calvin L. Stevens, a professor of chemistry at Wayne State University and a Parke-Davis consultant. It was known by the developmental code name CI-581. After promising preclinical research in animals, ketamine was tested in human prisoners in 1964. These investigations demonstrated ketamine's short duration of action and reduced behavioral toxicity made it a favorable choice over phencyclidine (PCP) as an anesthetic. The researchers wanted to call the state of ketamine anesthesia "dreaming", but Parke-Davis did not approve of the name. Hearing about this problem and the "disconnected" appearance of treated people, Mrs. Edward F. Domino, the wife of one of the pharmacologists working on ketamine, suggested "dissociative anesthesia". Ketamine was first described in the literature in 1963 and its effects in humans were first described by Edward F. Domino and colleagues in 1965. Following FDA approval in 1970, ketamine anesthesia was first given to American soldiers during the Vietnam War. The discovery of antidepressive action of ketamine in 2000 has been described as the single most important advance in the treatment of depression in more than 50 years. It has sparked interest in NMDA receptor antagonists for depression, and has shifted the direction of antidepressant research and development.
Genes regulated by the vitamin D receptor influence a wide range of physiological processes beyond calcium homeostasis and bone metabolism. They contribute to immune function, cellular signaling, and even blood coagulation, demonstrating the broad impact of vitamin D-regulated genes on human physiology. Examples of these genes are outlined below. Vitamin D receptor-regulated genes involved in vitamin D metabolism are CYP27B1, which encodes the enzyme that produces active vitamin D. and CYP24A1, which encodes the enzyme responsible for degrading active vitamin D, In the area of calcium homeostasis and bone metabolism, several genes are regulated by vitamin D. These include TNFSF11 (RANKL), essential for bone metabolism; SPP1 (Osteopontin), which is important for bone metabolism; and BGLAP (Osteocalcin), which is involved in bone mineralization. Additional genes include TRPV6, a calcium channel critical for intestinal calcium absorption; S100G (Calbindin-D9k), a calcium-binding protein that enables calcium translocation in enterocytes; ATP2B1 (PMCA1b), a plasma membrane calcium ATPase involved in calcium extrusion from the cell; and the S100A family of genes, which encode calcium-binding proteins involved in various cellular processes. Vitamin D also plays a role in immune function, influencing genes such as CAMP (Cathelicidin Antimicrobial Peptide), which is involved in innate immune responses; CD14, which participates in innate immune responses; and HLA class II genes, which are important for adaptive immune function.
Sources: en.wikipedia.org
This provided ammunition to a nationalistic and antisemitic communist party faction headed by Mieczysław Moczar that was opposed to Gomułka's leadership. Using the context of the military victory of Israel in the Six-Day War of 1967, some in the Polish communist leadership waged an antisemitic campaign against the remnants of the Jewish community in Poland. The targets of this campaign were accused of disloyalty and active sympathy with Israeli aggression. Branded "Zionists", they were scapegoated and blamed for the unrest in March 1968, which eventually led to the emigration of much of Poland's remaining Jewish population (about 15,000 Polish citizens left the country). With the active support of the Gomułka regime, the Polish People's Army took part in the infamous Warsaw Pact invasion of Czechoslovakia in August 1968, after the Brezhnev Doctrine was informally announced. In the final major achievement of Gomułka diplomacy, the governments of Poland and West Germany signed in December 1970 the Treaty of Warsaw, which normalized their relations and made possible meaningful cooperation in a number of areas of bilateral interest. In particular, West Germany recognized the post-World War II de facto border between Poland and East Germany.
Veratridine acts as a neurotoxin by increasing nerve excitability. It binds to binding site 2 on the voltage-gated sodium channels (the same site bound by batrachotoxin, aconitine, and grayanotoxin), leading to persistent activation. Veratridine inhibits sodium channel inactivation by shifting the activation threshold toward a more negative potential. The resulting influx of Na+ also leads to the increase of intracellular Ca2+ concentrations, causing the overproduction of reactive oxygen species responsible for neuronal damage. Veratridine is readily absorbed through the skin and mucous membranes and through ingestion. The tissues most affected are the heart, nerves, and skeletal muscles: main symptoms of veratridine toxicity include severe nausea, bradycardia, hypotension, difficulty breathing, salivation, and muscle weakness. Treatment involves the administration of activated charcoal, atropine, and benzodiazepines (if the affected individual is seizing). Veratridine's ability to depolarize cells by affecting sodium channels lends it its applicability as a neuropharmacological tool for the study of electrical properties of nerve and muscle fibers. It has also been tested as a treatment for myasthenia gravis, in light of its potential to increase muscle responses to motor neuron stimulation. Furthermore, this compound has recently been reported to increase sperm progressive motility (although it does not produce hyperactivation by itself).
=== Computing and telecommunications === Candidate recommendation, in W3C recommendations Carriage return, a new line of text in typing and computing Challenge-response spam filtering Code review, a systematic examination of computer source code during development Cognitive radio, an outgrowth of software-defined radio Cognitive robotics Control register Card reader
=== Chemicals === BASF produces a wide range of chemicals such as solvents, amines, resins, glues, electronic-grade chemicals, industrial gases, basic petrochemicals, and inorganic chemicals. The most important customers for this segment are the pharmaceutical, construction, textile, and automotive industries.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.